Quick Menu

Upcoming Journals

Asian Journal of Research in Medical and Pharmaceutical Sciences

Asian Journal of Research in Medical and Pharmaceutical Sciences, 2457-0745,Vol.: 4, Issue.: 1

Short Research Article

Efficacy of Ceftriaxone+Sulbactam+EDTA Combination for Complicated Urinary Tract Infection Patients: A Retrospective Case Series


Reema Kashiva1*, Dileep Mane1 and Danish Memon1

1Department of Medicine, Noble Hospital, 153, Magarpatta City Road, Hadapsar, Pune, Maharashtra 411013, India.


Article Information


(1) Anoja Priyadarshani Attanayake, Department of Biochemistry, Faculty of Medicine, University of Ruhuna, Sri Lanka.


(1) Akobi Oliver Adeyemi, Nigeria.

(2) Rutuja Raval, Gujarat University, India.

Complete Peer review History: http://www.sciencedomain.org/review-history/25211




Background: In India, antimicrobial resistance (AMR) remains a major challenge for treatment of infectious diseases mainly due to inappropriate and high consumption of antibiotics. Judicious choice of antibiotics and its optimistic utilization can be one of the potent ways to control the epidemic rise in AMR. The objective of this case series was to determine the clinical utility of antibiotic adjuvant entity (CSE-1034) (Ceftriaxone+Sulbactam+EDTA) in complicated urinary tract infection (cUTI) cases.

Methods: Patients suffering from multi-drug resistant (MDR) cUTIs and treated with CSE-1034 as monotherapy or combination therapy were screened and further analyzed. CSE-1034 therapy was started empirically in all these subjects and continued or discontinued based on culture sensitivity profile and clinical outcome. All the statistical analysis was performed using Chi-square test.

Results: 20 culture-positive patients with mean age of 51±7.3 years were included in this case series. The most common pathogen isolated was E. coli (60%) followed by K. pneumonia (25%) and A. baumannii (15%). Culture sensitivity profile has shown that pathogens isolated from all subjects showed no sensitivity to Cefazolin, Ceftriaxone, Cefipime, 25% to Pipericillin-Tazobactam (pip-taz), 20% to Cefaperozone-Sulbactam, 5% to fluoroquinolones and 90% to Meropenem. Susceptibility pattern to CSE-1034 and Colistin was 100%. 90% (18/20) patients treated empirically with CSE-1034 were cured with CSE-1034 monotherapy and 10% (2/20) with CSE-1034+Levofloxacin combination therapy.

Conclusion: From this case series, it can be suggested that CSE-134 alone or in combination with Levofloxacin appears to be an effective drug for treatment of MDR cUTI and can serve as effective replacement to Pip-Taz and β-lactam/β-lactam inhibitor combinations.


Keywords :

Complicated UTI; CSE-1034; multi-drug resistance.


Full Article - PDF    Page 1-7    Article Metrics


DOI : 10.9734/AJRIMPS/2018/41914

Review History    Comments

Search this site

Advanced Search

Announcement & News

Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and its editors

We are happy to inform that Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and ...

ISI Thomson Reuters selected British Journal of Pharmaceutical Research for Emerging Sources Citation Index

We are delighted to inform that ISI Thomson Reuters selected British Journal of Pharmaceutical Resea...

SCOPUS selected Annual Research & Review in Biology (ARRB)

We are delighted to inform that famous indexing organization SCOPUS (from Elsevier) selected  A...

Index Copernicus Evaluation Result Released

We are delighted to inform that Index Copernicus (a leading indexing organization from Pol...

Journal Repository (JR): Permanent Digital Archiving of SDI journals

SDI is happy to announce that all our journals are now permanently archived in Journal Repository (J...

SDI journal got 35th ranking in Publons

We are delighted to announce (as of 04/01/2016) that British Journal of Medicine and Medical Re...

Growth of SDI and world publication market

As of 2014, total 25,064 journals are competing in World market of journal publication. In 2011, tot...

Science (IF: 31) report confirmed the high standard of SDI journal

As per a recent report (Link) of Science journal (present Impact factor 31), one of our journal (Bri...

SDI introduced Post-publication peer review by its comment section

SDI journals encourage Post-publication peer review by its comment section   Policy details a...

SDI promotes transparent Advanced OPEN peer review

We have migrated to transparent and toughest ‘Advanced OPEN peer review’ system (...


  • No Awards listed.

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition   |   Privacy Policy   |   Join Us   |   Help   |   Contact Us
© Copyright 2010-2018, SCIENCEDOMAIN international. All rights reserved.